The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 2): Clinical experience in children

International Journal of Clinical Practice

Volumn 58, Issue 8, 2004, Pages 786-794

  van Schayck, C P ^a   Donnell, D ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b 3M Drug Delivery Systems   (United Kingdom)

Author keywords

Ashtma; Children; QVAR

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHARCOAL; CHLOROFLUOROCARBON; FLUTICASONE; PLACEBO;

ADOLESCENT; ADRENAL FUNCTION; ASTHMA; BONE METABOLISM; BRONCHITIS; CHILD; CLINICAL TRIAL; COUGHING; DEVICE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GROWTH; HUMAN; METERED DOSE INHALER; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; RHINITIS; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; CHILD; HUMANS; HYDROCARBONS, FLUORINATED; LUNG; TREATMENT OUTCOME;

EID: 4544338755     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00274.x     Document Type: Review

References (18)

1. Leach CL, Davidson PI, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-53.
2. Leach CL. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999; 104: S250-2.
3. Dolovich MB, Rhem R, Gerrard L, Coates G. Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma. Am J Respir Crit Care Med 2000; 61: A33. [Abstract].
4. Conway JH, Walker P, Perkins G et al. Lung deposition characteristics of HFA- 134a beclomethasone diproprionate delivered via an Autohaler. Eur Respir J 1999; 14 (Suppl. 30): 196s.
5. Vanden Burgt J, Busse W, Martin R et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106: 1209-26.
6. Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclomethasone diproprionate extrafine aerosol) in asthma (Part 1): an update of clinical experience in adults. Int J Clin Pract. Submitted.
7. Busse W, Brazinsky S, Jacobson K et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-22.
8. Harrison LI, Kurup S, Chen L-Z et al. Pharmacokinetic comparison of beclomethasone dipropionate extrafine aerosol from two inhaler devices in children with asthma. Eur J Clin Pharmacol 2002; 58: 191-5.
9. Agertoft L, Laulund LW, Harrison LI, Pedersen S. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol 2003; 35: 192-9.
10. Devadason SG, Huang T, Walker S et al. Distribution of technetium-99m-labelled QVAR™ delivered using an Autohaler™ device in children. Eur Respir J 2003; 21: 1007-11.
11. Agertoft L, Petersen RH, Pedersen S. A double blind, crossover, exercise challenge study in children comparing beclomethasone extrafine aerosol (HFA-BDP) dosed once daily (50 μg and 100 μg) with placebo. Presented at the XXII Congress of the European Academy of Allergology and Clinical Immunology, Paris, France 7-11 June 2003. Allergy 2003; 58 (74 Suppl.): 23. [Poster abstract 69].
12. Nayak A, Lanier R, Weinstein S et al. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma. A 12-week, randomized, double-blind, placebo-controlled study. Chest 2002; 122: 1956-65.
13. Ruff ME, Szefler SJ, Meltzer EO, Berger WE. Efficacy and safety of extrafine beclomethasone dipropionate aerosol therapy in children with asthma: a twelve-week placebo-controlled trial. Pediatr Asthma Allergy Immunol 2003; 16: 1-13. [Correction in Pediatr Asthma Allergy Immunol 2003; 16: 115].
14. Szefler SJ, Warner J, Staab D et al. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open label, randomized trial. J Allergy Clin Immunol 2002; 110: 45-50.
15. Pedersen S, Warner J, Wahn U et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109: 92.
16. Scheinmann P, Staab D, de Boeck C et al. A double-blind comparison of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma. Presented at the XXII Congress of the European Academy of Allergology and Clinical Immunology, Paris, France, 7-11 June 2003. Allergy 2003; 58 (74 Suppl.): 135. [Poster abstract 445].
17. Price D, Van Aalderen WMC, De Baets FM, Price J. A double-blind comparison of fluticasone (FP) and beclomethasone extrafine aerosol (HFA-BDP) in children with symptomatic mild to moderate asthma. Presented at the XXII Congress of the European Academy of Allergology and Clinical Immunology, Paris, France, 7-11 June 2003. Allergy 2003; 58 (74 Suppl): 177. [Poster abstract 596].
18. Randell TL, Donaghue KC, Ambler GR et al. Safety of the newer inhaled corticosteroids in childhood asthma. Pediatr Drugs Rev 2003; 5: 481-504.